Antonia Riva-Frizberg
Co-CEO

This startup provides a home-use capnometer that combines hardware with AI-powered software and a mobile app. This device allows individuals with lung disease to monitor their respiratory health, enabling better self-management and timely intervention.
Funding not disclosed

Co-CEO
Patients with chronic lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD), are prone to carbon dioxide (pCO2) retention, which can lead to hypercapnia and other severe health complications. Current methods for monitoring pCO2 levels typically require invasive blood gas analysis performed in a clinical setting, limiting the frequency and convenience of testing. This lack of accessible monitoring can delay timely intervention and negatively impact patient outcomes.
Lumetry Diagnostics offers a non-invasive, at-home breath gas analysis solution designed to monitor lung vitality and CO2 retention in patients with lung diseases. The system combines a user-friendly capnometer with proprietary AI algorithms and a mobile application to provide immediate results on a patient's smartphone, tablet, or desktop. By enabling daily monitoring via natural breathing, Lumetry empowers patients to proactively manage their condition, react to pCO2 changes in real-time, and potentially avoid CO2 poisoning and hospitalization. The solution aims to provide a less invasive alternative to blood gas analysis, offering objective monitoring for both patients and doctors, increased self-control, and reduced anxiety related to hospitalization.
The primary target audience includes individuals with chronic lung diseases, specifically COPD, who require regular monitoring of their respiratory health, as well as pulmonologists and other healthcare providers involved in the management of these patients.